U.S. Markets close in 4 hrs 49 mins
  • S&P 500

    3,950.52
    -13.42 (-0.34%)
     
  • Dow 30

    33,733.78
    -115.68 (-0.34%)
     
  • Nasdaq

    10,990.00
    -59.50 (-0.54%)
     
  • Russell 2000

    1,843.60
    +12.63 (+0.69%)
     
  • Crude Oil

    79.14
    +1.90 (+2.46%)
     
  • Gold

    1,769.10
    +13.80 (+0.79%)
     
  • Silver

    21.55
    +0.42 (+1.99%)
     
  • EUR/USD

    1.0344
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    3.7270
    +0.0240 (+0.65%)
     
  • Vix

    21.93
    -0.28 (-1.26%)
     
  • GBP/USD

    1.1980
    +0.0015 (+0.1282%)
     
  • USD/JPY

    138.3580
    -0.5430 (-0.3909%)
     
  • BTC-USD

    16,389.06
    +268.45 (+1.67%)
     
  • CMC Crypto 200

    387.11
    -1.62 (-0.42%)
     
  • FTSE 100

    7,529.79
    +55.77 (+0.75%)
     
  • Nikkei 225

    28,027.84
    -134.99 (-0.48%)
     

Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate

  • Adial Pharmaceuticals Inc's (NASDAQ: ADIL) subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain.

  • The study was conducted in four groups of ten rats that underwent surgical injury of the sciatic nerve.

  • At 30 minutes post-dose, PNV-5030 reduced pain by 43% compared to the control group, while acetaminophen (APAP) doses did not have a significant effect.

  • PNV-5030 also demonstrated a 49% improvement in pain reduction over acetaminophen.

  • Also ReadAdial Pharma's Subsidiary Shows Encouraging Preclinical Action For Inflammatory Bowel Disease Candidate

  • At 60 minutes post-dose, PNV-5030 reduced pain by 76% compared to the control group. PNV-5030 also demonstrated a 53% improvement in pain reduction over acetaminophen.

  • At 120 minutes post-dose, PNV-5030 reduced pain by 62% compared to the control group and by 56% at 180 minutes post-dose.

  • PNV-5030 has been tested to be more than 1000-fold selective over the adenosine A1 receptor. Historically, when selectivity has been achieved over the A1 receptor, water solubility has decreased, making biodistribution challenging.

  • However, PNV-5030 has demonstrated more than 50 times greater solubility than other known selective adenosine compounds of the same class and has shown it achieves the necessary biodistribution.

  • Price Action: ADIL shares are down 1.28% at $0.37 on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.